ByTrending Posts
Is China Becoming a Power Center for AI-Led…
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
Is the U.S. Reopening the Door to Coverage…
23 January 2026 Executive Summary The expiration of enhanced Affordable Care Act (ACA) subsidies is continuing to drive…
Does the U.S. Exit from WHO Redefine Global…
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Does the U.S. Exit from WHO Redefine Global…
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS…
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics, a…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS…
22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics,…
Can Global Partnerships Future-Proof Epidemic Preparedness? SK bioscience,…
23 January 2026 Executive Summary A global vaccine partnership has been established between SK bioscience, MSD (Merck &…
Is Strategic Out-Licensing the Fastest Path to Global…
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…
Is GSK Buying Its Way Past the Patent…
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
Trending Posts
Latest Stories
How Are Biopharma Giants Deploying Agentic AI to Revolutionize R&D Over the Next 5 Years?
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck,…
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22 Trial, Unleashing Multi-Oncology Disruption
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following…
Gallery
